<DOC>
	<DOCNO>NCT02699710</DOCNO>
	<brief_summary>This study Phase I , single center , randomize ( Parts 1 2 ) , open-label , 3 part study . Parts 1 2 2-way crossover , 1-fixed sequence , 3-period design investigate effect formulation , food rabeprazole PK GDC-0853 healthy male female ( non-childbearing potential ) participant . Part 3 fixed-sequence study 3 treatment characterize steady-state PK GDC-0853 tablet ; effect simultaneous administration single dose methotrexate steady-state kinetics GDC-0853 ; effect dose GDC-0853 steady-state single dose PK methotrexate healthy male participant .</brief_summary>
	<brief_title>Effect Food , Rabeprazole , Methotrexate Formulation Pharmacokinetics ( PK ) GDC-0853 Effect GDC-0853 PK Methotrexate Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Rabeprazole</mesh_term>
	<mesh_term>Folic Acid</mesh_term>
	<mesh_term>Vitamin B Complex</mesh_term>
	<criteria>Within body mass index range 18.0 31.0 kilogram per square meter ( kg/m^2 ) , inclusive For woman postmenopausal ( great equal [ &gt; /= ] 12 month nontherapyinduced amenorrhea ) surgically sterile ( absence ovary and/or uterus ) : participant exclude For men : agreement use condom plus additional contraceptive method partner treatment period least 93 day last dose study drug agreement refrain donate sperm period Significant history clinical manifestation significant metabolic , allergic , dermatological , hepatic , renal , hematological , pulmonary , cardiovascular , gastrointestinal , neurological , psychiatric disorder ( determined investigator ) History significant hypersensitivity , intolerance , allergy drug compound , food , substance , unless approve investigator Participants previously enrol study participation investigational study drug trial receipt investigational study drug occur within 90 day prior Period 1 Checkin ( Day 1 ) History malignancy , except completely excise basal cell carcinoma squamous cell carcinoma skin cervical carcinoma situ Female participant pregnant , lactate breastfeed Current treatment medication well know prolong QT interval Failure satisfy investigator fitness participate reason</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>